YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Legend Biotech (LEGN) moved back into focus after releasing five-year follow-up data from its CARTITUDE-2 Cohort A study of CARVYKTI in relapsed or refractory multiple myeloma patients. Despite the encouraging CARTITUDE-2 update, Legend Bi…
Healthcare stocks were little changed late Friday afternoon with the NYSE Healthcare Index and the S PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Legend Biotech's (LEGN) multiple myeloma therapy Carvykti is facing growing competitive pressure as PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
Legend Biotech USA Inc. Annual program will award funding to early-career healthcare professionals advancing research, education, and innovation in multiple myeloma BRIDGEWATER, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corpor…
Asian equities traded in the US as American depositary receipts were lower on Tuesday morning, decre PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Legend Biotech USA Inc. Five-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line RRMM BRIDGEWATER, N.J., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Legend Biotech…
Legend Biotech (NASDAQ:LEGN) presents a compelling equity thesis centered on transforming breakthrough oncology innovation into a high-margin, cash-generative cell therapy franchise. Maintaining a fortress balance sheet anchored by approxi…
Legend Biotech USA Inc. Ingrid Zhang, an accomplished global biopharmaceutical leader, joins Legend Biotech following a comprehensive Board-led search process BRIDGEWATER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation…
Legend Biotech USA Inc. Updated long-term follow-up data will be presented from CARTITUDE-2 Cohort A in patients with lenalidomide-refractory multiple myeloma after 1-3 prior lines of therapy Real-world evidence and post-authorization safe…
Legend Biotech (LEGN) drew fresh investor attention after announcing that interim CEO Alan Bash will speak at the Morgan Stanley Global Healthcare Conference on September 15, 2026. The company plans to highlight its CAR-T focus and commerc…
Legend Biotech stock has fallen sharply over the past few years, yet the broader valuation checks still lean cheap based on current market multiples. That gap between a weak share price record and a relatively positive valuation screen is…
Legend Biotech USA Inc. BRIDGEWATER N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Alan Bash, interim Chief Executive Officer, will…
You probably know Johnson & Johnson (NYSE: JNJ) mainly for its prescription medications. Some may be familiar with the company's medical devices. But J&J has another role that many people may not know about: It's a healthcare investor. Joh…
[Patients Receiving Medical Infusions in a Clinical Setting with Nurse Assistance] FatCamera/iStock via Getty Images Earlier this week, shares of Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and partner Merck (MRK [https://seeking…
Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.2% and t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Pre-Market Stock Futures: Futures are trading modestly higher as we have arrived at the day everyone on Wall Street has circled on their calendars. The July consumer price index will be released at 8:30 AM EDT, and the producer price index…
(RTTNews) - Legend Biotech Corporation (LEGN) released financial results for the second quarter ended June 30, 2026. The commercial-stage company turned profitable in the second quarter, compared with a loss in the prior-year quarter, driv…
Image source: The Motley Fool. DATE Tuesday, Aug. 11, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Interim Chief Executive Officer - Alan BashChief Financial Officer - Carlos SantosInterim Head of R&D - Yuhong QiuDirector of Investor Relations -…
This article first appeared on GuruFocus. Total Revenue: Increased 52% year over year, driven by continued CARVYKTI demand and commercial expansion. CARVYKTI Net Trade Sales: Approximately $657 million worldwide, representing 50% year-over…
Quick Read LEGN surged 6% as Q2 revenue of $388M beat estimates and adjusted EPS of $0.16 doubled consensus, marking the company's first-ever profitable quarter. CARVYKTI net sales hit $657M, up 50%, with JNJ co-developer Janssen supportin…
Pipette dropping liquid into a test tube ©Adobe Stock Images Legend Biotech Corporation (NASDAQ:LEGN) shares gained 5.5% in pre-market trading on Tuesday after the pharmaceutical company delivered better-than-expected second-quarter earnin…
Key Points Interested in Legend Biotech Corporation Sponsored ADR? Here are five stocks we like better. CARVYKTI sales rose sharply: Worldwide net trade sales increased 50% year over year to approximately $657 million, driven by earlier-li…
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2% and the actively traded Invesco QQQ Trust (QQQ) was 0.4% higher in Tuesday's premarket activity as stalled US-Iran talks weigh on investors.US stock futures wer…
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. The CEO who helped guide development of the top-selling cell therapy for multiple myeloma wil…
Legend Biotech USA Inc. CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 50% versus second quarter of 2025 to approximately $657 million Expanded CARVYKTI® availability to 348 global sites and 19 global markets wi…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Legend Biotech stock has seen a steep share price decline over the past few years, yet the latest valuation checks stil…
Legend Biotech recently announced that Ying Huang, Ph.D., has stepped down as Chief Executive Officer and Board member, effective July 24, 2026, with CARVYKTI business unit President Alan Bash appointed as Interim CEO and Dr. Huang staying…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Legend Biotech, listed as NasdaqGS:LEGN, announced that CEO Ying Hu…
Legend Biotech USA Inc. BRIDGEWATER N.J., July 28, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 a.m. ET on Tuesday,…
Legend Biotech USA Inc. Ying Huang, Ph.D., steps down as Chief Executive Officer and member of the Board of Directors; will remain as an advisor through August to support a smooth transition Alan Bash, current President of the CARVYKTI Bus…
Ying Huang, Ph.D., steps down as Chief Executive Officer and member of the Board of Directors; will remain as an advisor through August to support a smooth transitionAlan Bash, current President of the CARVYKTI Business Unit, appointed Int…
Key Points Legend and BioNTech are commercial-stage biotechs. Legend shares its Carvyki revenue with Johnson & Johnson. BioNTech has six clinical trial readouts scheduled this year.10 stocks we like better than Legend Biotech › Dealmaking…
Dealmaking is back with a vengeance in the pharmaceutical sector this year. According to a report by PwC, there were more than $65 billion in pharma and life sciences mergers & acquisitions in the first quarter, the best quarter for the se…
We recently compiled a list of the 10 Best Healthcare Stocks to Buy According to Wall Street Analysts. Legend Biotech Corporation (NASDAQ:LEGN) is among the best healthcare stocks. TheFly reported on June 3 that UBS increased its price tar…
Quick Read Legend Biotech (LEGN) generates $1 billion in CAR-T revenue with J&J already embedded as acquirer, yet trades at roughly half its $58 analyst price target. Aleniglipron posted 16% placebo-adjusted weight loss at 44 weeks, placin…
(RTTNews) - Calidi Biotherapeutics, Inc. (CLDI) announced the appointment of Corsee Sanders as an independent director on the company's Board of Directors, effective from June 17, 2026. Sanders previously held several leadership positions…